<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2221-2434</journal-id>
<journal-title><![CDATA[Revista Finlay]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. Finlay]]></abbrev-journal-title>
<issn>2221-2434</issn>
<publisher>
<publisher-name><![CDATA[Universidad de Ciencias Médicas de Cienfuegos. Centro Provincial de información de Ciencias Médicas]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2221-24342021000400352</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Identificación del riesgo de trombosis en pacientes con padecimientos oncológicos ambulatorios en quimioterapia]]></article-title>
<article-title xml:lang="en"><![CDATA[Identification of Thrombosis Risk in Patients with Suffering Cancer Conditions Undergoing Chemotherapy]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Jiménez Abraham]]></surname>
<given-names><![CDATA[Maylín]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Fernández Águila]]></surname>
<given-names><![CDATA[Julio Dámaso]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Vasallo Díaz]]></surname>
<given-names><![CDATA[Ana Lourdes]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Calzada Urquiola]]></surname>
<given-names><![CDATA[Dayana]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital General Universitario Dr. Gustavo Aldereguía Lima.  ]]></institution>
<addr-line><![CDATA[Cienfuegos ]]></addr-line>
<country>Cuba</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2021</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2021</year>
</pub-date>
<volume>11</volume>
<numero>4</numero>
<fpage>352</fpage>
<lpage>358</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_arttext&amp;pid=S2221-24342021000400352&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_abstract&amp;pid=S2221-24342021000400352&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_pdf&amp;pid=S2221-24342021000400352&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN  Fundamento  existe una relación establecida entre el cáncer y la aparición y desarrollo de enfermedad tromboembólica. Se hace necesario identificar a los pacientes con un riesgo aumentado de tromboembolismo venoso utilizando escalas predictivas para individualizar el riesgo.  Objetivo  identificar el riesgo de trombosis en el paciente con padecimientos oncológicos ambulatorios en quimioterapia.  Método  se realizó un estudio descriptivo de corte transversal, en una serie de casos, atendidos en el Servicio de Oncología Clínica del Hospital General Universitario Dr. Gustavo Aldereguía Lima, de Cienfuegos, en el período comprendido entre el primero de junio de 2020 hasta el treinta de abril de 2021. La información se obtuvo del expediente clínico y un modelo recolector de datos. Las variables analizadas fueron: edad, sexo, sitio del tumor primario, conteo de plaquetas previo a la quimioterapia, niveles de hemoglobina sérica, uso de eritropoyetina, conteo leucocitario previo a la quimioterapia e índice de masa corporal. Los datos obtenidos se procesaron mediante el programa estadístico SPSS versión 21 y los resultados se presentan en tablas mediante números absolutos y porcientos.  Resultados  el grupo de edad más frecuente fue el de 60 años y más con 77 pacientes (51,3 %), del sexo masculino 45 (30 %). La aplicación del modelo de predicción de Khorana marcó un porcentaje relevante (26 %) de pacientes con riesgo intermedio y alto de trombosis.  Conclusiones  la investigación muestra una población adulta mayoritariamente envejecida, con factores de riesgo de trombosis relacionados con el paciente, la enfermedad oncológica y los tratamientos sistémicos.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT  Background: there is an established relationship between cancer and the appearance and development of thromboembolic disease. It is necessary to identify patients with an increased risk of venous thromboembolism using predictive scales to individualize the risk.  Objective: to identify the risk of thrombosis in patients with suffering cancer conditions undergoing chemotherapy.  Method: a series of cases descriptive cross-sectional study, treated at the Clinical Oncology Service of the Dr. Gustavo Aldereguía Lima University General Hospital, Cienfuegos, from June the 1st, 2020 to April 30th, 2021. The information was obtained from the clinical record and a data collection model. The variables analyzed were: age, sex, site of the primary tumor, platelet count prior to chemotherapy, serum hemoglobin levels, erythropoietin use, leukocyte count prior to chemotherapy, and body mass index. The data obtained were processed using the SPSS version 21 statistical program and the results are presented in tables using absolute numbers and percentages.  Results: the most frequent age group was 60 years old and over with 77 patients (51.3 %), 45 (30 %) male. The application of the Khorana score marked a relevant percentage (26 %) of patients with intermediate and high risk of thrombosis.  Conclusions: the research shows a mostly aged adult population, with risk factors for thrombosis related to the patient, oncological disease and systemic treatments.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[cáncer]]></kwd>
<kwd lng="es"><![CDATA[tromboembolismo venoso]]></kwd>
<kwd lng="es"><![CDATA[factores de riesgo]]></kwd>
<kwd lng="en"><![CDATA[cancer]]></kwd>
<kwd lng="en"><![CDATA[venous thromboembolism]]></kwd>
<kwd lng="en"><![CDATA[risk factors]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="book">
<collab>Organización Mundial de la Salud 2020</collab>
<source><![CDATA[Cáncer. Datos y Cifras]]></source>
<year>2020</year>
<publisher-loc><![CDATA[Washington ]]></publisher-loc>
<publisher-name><![CDATA[OMS]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sack]]></surname>
<given-names><![CDATA[GH]]></given-names>
</name>
<name>
<surname><![CDATA[Levin]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Bell]]></surname>
<given-names><![CDATA[WR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Trousseau's syndrome and other manifestations of chronic disseminated coagulopathy in patients with neoplasms clinical, pathophysiologic, and therapeutic features]]></article-title>
<source><![CDATA[Medicine]]></source>
<year>1977</year>
<volume>56</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1-37</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Epstein]]></surname>
<given-names><![CDATA[AS]]></given-names>
</name>
<name>
<surname><![CDATA[Soff]]></surname>
<given-names><![CDATA[GA]]></given-names>
</name>
<name>
<surname><![CDATA[Capanu]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Crosbie]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Shah]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Kelsen]]></surname>
<given-names><![CDATA[DP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Analysis of incidence and clinical outcomes in patients with thromboembolic events and invasive exocrine pancreatic cancer]]></article-title>
<source><![CDATA[Cancer]]></source>
<year>2012</year>
<volume>118</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>3053-61</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chew]]></surname>
<given-names><![CDATA[HK]]></given-names>
</name>
<name>
<surname><![CDATA[Wun]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Harvey]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Zhou]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[White]]></surname>
<given-names><![CDATA[RH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Incidence of venous thromboembolism and its effect on survival among patients with common cancers]]></article-title>
<source><![CDATA[Arch Intern Med]]></source>
<year>2006</year>
<volume>166</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>458-64</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Falanga]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Russo]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Verzeroli]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mechanisms of thrombosis in cancer]]></article-title>
<source><![CDATA[Thromb Res.]]></source>
<year>2013</year>
<volume>131</volume>
<numero>^s1</numero>
<issue>^s1</issue>
<supplement>1</supplement>
<page-range>S59-62</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Martínez]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Antonio]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Borrega]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Marín]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Salgado]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Navarro]]></surname>
<given-names><![CDATA[LM]]></given-names>
</name>
</person-group>
<source><![CDATA[II Consenso SEOM sobre la Enfermedad Tromboembólica en Pacientes con Cáncer]]></source>
<year>2013</year>
<publisher-loc><![CDATA[Barcelona ]]></publisher-loc>
<publisher-name><![CDATA[Sociedad Española de Oncología Médica]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Khorana]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
<name>
<surname><![CDATA[Kuderer]]></surname>
<given-names><![CDATA[NM]]></given-names>
</name>
<name>
<surname><![CDATA[Culakova]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Lyman]]></surname>
<given-names><![CDATA[GH]]></given-names>
</name>
<name>
<surname><![CDATA[Francis]]></surname>
<given-names><![CDATA[CW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Development and validation of a predictive model for chemotherapy associated thrombosis]]></article-title>
<source><![CDATA[Blood]]></source>
<year>2008</year>
<volume>111</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>4902-7</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bustillo]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[López]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Feito]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[García]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Álvarez]]></surname>
<given-names><![CDATA[Y.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Trombosis venosa profunda en adultos mayores con cáncer]]></article-title>
<source><![CDATA[Rev Cubana Angiol Cir Vasc]]></source>
<year>2015</year>
<volume>16</volume>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kourlaba]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Relakis]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Mylonas]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Kapaki]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Kontodimas]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Holm]]></surname>
<given-names><![CDATA[MV]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The humanistic and economic burden of venous thromboembolism in cancer patients a systematic review]]></article-title>
<source><![CDATA[Blood Coagul Fibrinolysis]]></source>
<year>2015</year>
<volume>26</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>13-31</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Alfonso]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Inguanzo]]></surname>
<given-names><![CDATA[IB.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Síndrome de Trousseau como manifestación de neoplasia maligna]]></article-title>
<source><![CDATA[Invest Med Quir]]></source>
<year>2020</year>
<volume>12</volume>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Moore]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Adel]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Riedel]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Bhutani]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Feldman]]></surname>
<given-names><![CDATA[DR]]></given-names>
</name>
<name>
<surname><![CDATA[Tabbara]]></surname>
<given-names><![CDATA[NE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy a large retrospective analysis]]></article-title>
<source><![CDATA[J Clin Oncol]]></source>
<year>2011</year>
<volume>29</volume>
<numero>25</numero>
<issue>25</issue>
<page-range>3466-73</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ugarte]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Otero]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Ferrer]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Morillo]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Elías]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Jara]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Predictive Khorana's model in patients with venous thromboembolic disease and cancer]]></article-title>
<source><![CDATA[Med Clin (Barc)]]></source>
<year>2013</year>
<volume>141</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>479-81</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="book">
<collab>Parliamentary Thrombosis Group</collab>
<source><![CDATA[Venous Thromboembolism in Cancer: cancer chemotherapy and clots]]></source>
<year>2015</year>
<publisher-loc><![CDATA[London ]]></publisher-loc>
<publisher-name><![CDATA[Parliamentary Thrombosis Group]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B14">
<label>14.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Aronés]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Carrasco]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Delgado]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[López]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Incidencia de enfermedad tromboembólica en neoplasias malignas en cuatro hospitales de Lima]]></article-title>
<source><![CDATA[Rev Soc Perú Med Inter]]></source>
<year>2002</year>
<volume>15</volume>
<numero>2</numero>
<issue>2</issue>
</nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Khorana]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
<name>
<surname><![CDATA[Kuderer]]></surname>
<given-names><![CDATA[NM]]></given-names>
</name>
<name>
<surname><![CDATA[Culakova]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Lyman]]></surname>
<given-names><![CDATA[GH]]></given-names>
</name>
<name>
<surname><![CDATA[Francis]]></surname>
<given-names><![CDATA[CW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Development and validation of a predictive model of chemotherapy- associated thrombosis]]></article-title>
<source><![CDATA[Blood]]></source>
<year>2008</year>
<volume>111</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>4902-7</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Connolly]]></surname>
<given-names><![CDATA[GC]]></given-names>
</name>
<name>
<surname><![CDATA[Khorana]]></surname>
<given-names><![CDATA[AA.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Emerging risk stratification approaches to cancer- associated thrombosis: risk factor, biomarkers and e risk score.]]></article-title>
<source><![CDATA[Thromb Res]]></source>
<year>2010</year>
<volume>125</volume>
<numero>^s2</numero>
<issue>^s2</issue>
<supplement>2</supplement>
<page-range>1-7</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Khorana]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
<name>
<surname><![CDATA[Francis]]></surname>
<given-names><![CDATA[CW]]></given-names>
</name>
<name>
<surname><![CDATA[Culakova]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Lyman]]></surname>
<given-names><![CDATA[GH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Risk factors for chemotherapy- associated venous thromboembolism in a prospective observational study]]></article-title>
<source><![CDATA[Cancer]]></source>
<year>2005</year>
<volume>104</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>2822-9</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
